Home World News Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for... World News Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk for Recurrence of Cutaneous Squamous Cell Carcinoma By Ogkologos - June 18, 2025 841 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... April 9, 2025 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... March 23, 2021 Load more HOT NEWS Learning to Advocate for Yourself – An Important Skill! Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 FDA Approves Avapritinib for Advanced Systemic Mastocytosis FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or...
